Sanofi and GSK agree with UK government to supply up to 60 million doses of COVID-19 vaccine
PARIS and LONDON – 29 July 2020 – Sanofi and GSK reached an agreement, the subject of a final contract, with the British government to obtain up to 60 million doses of a COVID-19 vaccine. The candidate vaccine, developed through Sanofi in partnership with GSK, is based on the generation of recombinant protein used through Sanofi to produce a flu vaccine and the established pandemic adjuvant generation of GSK.
“With our GSK component, we are pleased to cooperate with the UK government and several other global countries and organisations as a component of our ongoing efforts to expand a safe and effective vaccine and ensure that it is held as temporarily as possible. The British government is in favor of this shared vision,” said Thomas Triomphe, executive vice president and global director of Sanofi Pasteur.
British Trade Secretary Alok Sharma said: “Our scientists and researchers are rushing to find a safe and effective vaccine at a speed and scale never before noticed. While this progress is indeed remarkable, there are no guarantees.”
“In the meantime, it is vital that we have quick access to a wide variety of promising vaccine candidates, such as GSK and Sanofi, to increase our chances of finding one that works so that we can help the public and save lives.”
Kate Bingham, chair of the UK government’s Vaccine Working Group, said: “With this agreement with GSK and Sanofi, the Vaccine Working Group can load the vaccine type to the 3 types of vaccines we have already obtained.
“The fact is that we will probably never get a vaccine and, if we get it, we need to be prepared to know that it is not a vaccine that prevents it from getting the virus, but a vaccine that reduces symptoms.”
Sanofi and GSK are dedicated to making vaccines for everyone
Active discussions are underway on the delivery of vaccines with global organizations, with the United States and the European Commission, France and Italy as part of the negotiating team. The components plan to gain a significant portion of the overall source capacity to be held internationally until 2021/22 for the COVID-19 Global Initiative (ACT), a global collaboration of government leaders, global fitness organizations, corporations and philanthropists to drive development. , production and equitable access to COVID-19 testing, remedies and vaccines.
On the line in the fight opposite COVID-19
Attachment file